Search Results - "Hollburg, W"

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry by Kaifie, A, Kirschner, M, Wolf, D, Maintz, C, Hänel, M, Gattermann, N, Gökkurt, E, Platzbecker, U, Hollburg, W, Göthert, J R, Parmentier, S, Lang, F, Hansen, R, Isfort, S, Schmitt, K, Jost, E, Serve, H, Ehninger, G, Berdel, W E, Brümmendorf, T H, Koschmieder, S

“…Patients with Ph-negative myeloproliferative neoplasms (MPN), such as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF),…”
Get full text

Palliative home care for patients with advanced haematological malignancies—a multicenter survey by Kaiser, F., Rudloff, L. v., Vehling-Kaiser, U., Hollburg, W., Nauck, F., Alt-Epping, B.

“…Patients with advanced haematological malignancies in non-curative settings suffer from complex physical symptoms and psychosocial distress, comparable to…”
Get full text

Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians by Kaifie, A., Isfort, S., Gattermann, N., Hollburg, W., Klausmann, M., Wolf, D., Maintz, C., Hänel, M., Goekkurt, E., Göthert, J. R., Platzbecker, U., Geer, T., Parmentier, S., Jost, E., Serve, H., Ehninger, G., Berdel, W. E., Brümmendorf, T. H., Koschmieder, Steffen

“…Philadelphia-negative myeloproliferative neoplasms (MPN) comprise a heterogeneous group of chronic hematological malignancies with significant variations in…”
Get full text

5073 POSTER Bevacizumab (Bev) Combined With Paclitaxel (Pac) as First-line Therapy for Metastatic Triple-negative Breast Cancer (TNBC) -Analysis of 147 Patients (pts) Treated in Routine Oncology Practice in Germany by Schneeweiss, A, Foerster, F, Hollburg, W, Tesch, H, Klare, P, Wuelfing, P, Distelrath, A, Schumacher, C, Steffens, C.C, Schmidt, M

Get full text

Abstract P2-16-03: Mature results on metastatic breast cancer patients with prolonged (≥1 year) exposure to first-line bevacizumab combined with paclitaxel from a large observation study by Schmidt, M, Schneeweiss, A, Förster, F, Geberth, M, Schumacher, C, Hollburg, W, Söling, U, Aktas, B, Kümmel, S

“…Abstract Background: Bevacizumab (BEV) combined with chemotherapy (CT) significantly improves progression-free survival (PFS) and response rate (RR) vs CT…”
Get full text

P1-14-04: Prolonged (≥1 Year) Exposure to First-Line Bevacizumab Combined with Paclitaxel in Patients with HER2−Negative Metastatic Breast Cancer Treated in a Routine Oncology Practice Study by Kuemmel, S, Schneeweiss, A, Foerster, FG, Geberth, M, Tesch, H, Klare, P, Schumacher, C, Hollburg, W, Soeling, U, Schmidt, M

“…Abstract Background: First-line bevacizumab (BEV) combined with weekly paclitaxel (PAC) significantly improves progression-free survival (PFS) and response…”
Get full text

Efficacy and safety of first-line bevacizumab (Bev) combined with paclitaxel (Pac): An observational study in 786 patients (pts) with HER2-negative metastatic breast cancer (mBC) by Klare, P., Foerster, F. G., Geberth, M., Schneeweiss, A., Tesch, H., Kuemmel, S., Schumacher, C., Hollburg, W., Soeling, U., Schmidt, M.

“…Abstract only…”
Get full text

Abstract P2-16-12: First-Line Bevacizumab Combined with Paclitaxel in Triple-Negative Locally Recurrent/Metastatic Breast Cancer: Subpopulation Analysis of 115 Patients Treated in Routine Oncology Practice in Germany by Schneeweiss, A, Foerster, FG, Hollburg, W, Tesch, H, Klare, P, Wuelfing, P, Distelrath, A, Schumacher, C, Steffens, C-C, Schubert, R, Widing, A, Kasper, C, Schmidt, M.

“…Abstract Background: Both progression-free survival (PFS) and response rate (RR) are significantly improved when bevacizumab (Bev) is combined with first-line…”
Get full text